SBS says ADMA investors may seek lead plaintiff role in securities class action

By Atlas Watchline Staff · Legal · August 2, 2026

Schall, Brown & Schwartz LLP says ADMA Biologics investors who bought shares during the stated class period may contact the firm about lead plaintiff appointments in a securities suit.

Schall, Brown & Schwartz LLP said Friday that investors in ADMA Biologics, Inc. who bought shares during a stated class period may seek lead plaintiff appointments in a securities class action tied to the company’s public statements.

The law firm said the case concerns alleged violations of federal securities laws, including Section 10(b), Section 20(a) and SEC Rule 10b-5. The release says the class period runs from Aug. 9, 2024, through March 25, 2026.

SBS said lead plaintiff appointment is not required to participate in any recovery.

In its press release, the firm said the complaint alleges ADMA made false and misleading statements, failed to disclose a related-party transaction, used channel stuffing to create the appearance of revenue and failed to maintain appropriate internal controls. The release also says investors suffered damages when the market learned the truth.

The press release did not provide additional detail about the underlying events, including the court where the case was filed, the case number, or any ruling or settlement. It also did not include ADMA’s response to the allegations.

Schall, Brown & Schwartz described itself in the release as a national shareholder rights litigation firm. It identified the company as ADMA Biologics, Inc., which trades on Nasdaq under the ticker ADMA.

The firm said shareholders who purchased ADMA shares during the class period may contact it about possible lead plaintiff appointments. The release listed Brian Schall and David Schwartz and gave the firm’s Los Angeles office address, phone number, website and email address.

The press release did not say when a court might consider lead plaintiff appointments or whether any hearing date has been set.

Sources

• PR Newswire: ADMA investors have opportunity to lead ADMA Biologics, Inc. securities fraud lawsuit with SBS Law

Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.

This is the AMP version of the article. Read the full article on Atlas Watchline.